首页 > 最新文献

Infection and Chemotherapy最新文献

英文 中文
Linezolid-Resistant Coagulase-Negative Staphylococci in a Tertiary Hospital: Molecular Epidemiology, Clinical Characteristics, and Outcomes.
IF 2.8 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-01 Epub Date: 2025-01-17 DOI: 10.3947/ic.2024.0111
Svetlana Rachina, Vladimir Gostev, Vyacheslav Pleshkov, Olga Karpova, Svetlana Topolyanskaya, Georgy Melkonyan, Marina Gladkikh, Khadizhat Zainalabidova, Polina Chulkova, Sergey Sidorenko

We report linezolid-resistant coagulase-negative Staphylococcus (LRCoNS) bacteremia at a tertiary hospital. LRCoNS with linezolid and tedizolid minimum inhibitory concentrations of >32 and 4-32 mg/L, respectively, were isolated from blood cultures of seven elderly patients who died post-bacteremia detection. Linezolid was administered to six of these patients at the time of LRCoNS isolation. Linezolid-resistant S. epidermidis ST5 isolates (LRSE) harboring mecA were isolated in seven of the nine episodes. Linezolid resistance is associated with mutations in the 23S rRNA, L3 and L4 ribosomal proteins, indigenous methyltransferases RlmN, and the presence of the cfr gene. All LRSE-ST5 genomes formed a single phylogenetic cluster.

{"title":"Linezolid-Resistant Coagulase-Negative Staphylococci in a Tertiary Hospital: Molecular Epidemiology, Clinical Characteristics, and Outcomes.","authors":"Svetlana Rachina, Vladimir Gostev, Vyacheslav Pleshkov, Olga Karpova, Svetlana Topolyanskaya, Georgy Melkonyan, Marina Gladkikh, Khadizhat Zainalabidova, Polina Chulkova, Sergey Sidorenko","doi":"10.3947/ic.2024.0111","DOIUrl":"10.3947/ic.2024.0111","url":null,"abstract":"<p><p>We report linezolid-resistant coagulase-negative <i>Staphylococcus</i> (LRCoNS) bacteremia at a tertiary hospital. LRCoNS with linezolid and tedizolid minimum inhibitory concentrations of >32 and 4-32 mg/L, respectively, were isolated from blood cultures of seven elderly patients who died post-bacteremia detection. Linezolid was administered to six of these patients at the time of LRCoNS isolation. Linezolid-resistant <i>S. epidermidis</i> ST5 isolates (LRSE) harboring <i>mec</i>A were isolated in seven of the nine episodes. Linezolid resistance is associated with mutations in the 23S rRNA, L3 and L4 ribosomal proteins, indigenous methyltransferases RlmN, and the presence of the <i>cfr</i> gene. All LRSE-ST5 genomes formed a single phylogenetic cluster.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"161-167"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phylogenetic Analysis of Escherichia coli according to Phenotypic Resistance in Urinary Tract Infections in Children, Lima, Peru.
IF 2.8 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-01 Epub Date: 2025-01-14 DOI: 10.3947/ic.2024.0101
Adriana Belén Prieto Farfan, Yesica Llimpe Mitma de Barrón, Melina Magali Mayorca Yarihuamán, Fortunato Martín Príncipe Laines, María Bertha Paredes Pérez, Jaeson Santos Calla Choque, Heli Jaime Barrón Pastor

Background: Phylogenetic studies are essential for understanding the virulence and resistance factors of bacteria, especially in evaluating their distribution within specific populations for effective infection control. Urinary tract infections (UTIs) caused by Escherichia coli are highly prevalent and pose significant health challenges from childhood to adulthood. The rising incidence of multidrug-resistant (MDR) strains highlights the urgent need for research aimed at developing preventive measures and epidemiological control strategies. This study aimed to analyze phylogenetically uropathogenic E. coli strains and their resistance phenotypes in children.

Materials and methods: A retrospective analysis was conducted on 111 urine culture samples collected from June 2023 to February 2024 at the Pediatric Emergency Hospital (PEH) in Lima, Peru. The phylogroups of E. coli were identified using Clermont's protocol based on polymerase chain reaction.

Results: UTIs were predominantly observed in females (85.6%) and infants under two years old (42.3%). The most frequent uropathogenic E. coli phylogroups were B2 (30.6%), D (29.7%), and A (25.2%). These phylogroups showed significant correlation with MDR and the production of extended spectrum beta-lactamases (ESBL).

Conclusion: At PEH, UTIs in children are primarily caused by uropathogenic E. coli from the B2 and D phylogroups, which demonstrate high virulence and resistance factors. The correlation between these phylogroups, MDR, and ESBL production, along with the increasing infection rates associated with phylogroup A, suggests a potential for horizontal gene transfer. This underscores the urgent need for vigilant control measures.

{"title":"Phylogenetic Analysis of <i>Escherichia coli</i> according to Phenotypic Resistance in Urinary Tract Infections in Children, Lima, Peru.","authors":"Adriana Belén Prieto Farfan, Yesica Llimpe Mitma de Barrón, Melina Magali Mayorca Yarihuamán, Fortunato Martín Príncipe Laines, María Bertha Paredes Pérez, Jaeson Santos Calla Choque, Heli Jaime Barrón Pastor","doi":"10.3947/ic.2024.0101","DOIUrl":"10.3947/ic.2024.0101","url":null,"abstract":"<p><strong>Background: </strong>Phylogenetic studies are essential for understanding the virulence and resistance factors of bacteria, especially in evaluating their distribution within specific populations for effective infection control. Urinary tract infections (UTIs) caused by <i>Escherichia coli</i> are highly prevalent and pose significant health challenges from childhood to adulthood. The rising incidence of multidrug-resistant (MDR) strains highlights the urgent need for research aimed at developing preventive measures and epidemiological control strategies. This study aimed to analyze phylogenetically uropathogenic <i>E. coli</i> strains and their resistance phenotypes in children.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted on 111 urine culture samples collected from June 2023 to February 2024 at the Pediatric Emergency Hospital (PEH) in Lima, Peru. The phylogroups of <i>E. coli</i> were identified using Clermont's protocol based on polymerase chain reaction.</p><p><strong>Results: </strong>UTIs were predominantly observed in females (85.6%) and infants under two years old (42.3%). The most frequent uropathogenic <i>E. coli</i> phylogroups were B2 (30.6%), D (29.7%), and A (25.2%). These phylogroups showed significant correlation with MDR and the production of extended spectrum beta-lactamases (ESBL).</p><p><strong>Conclusion: </strong>At PEH, UTIs in children are primarily caused by uropathogenic <i>E. coli</i> from the B2 and D phylogroups, which demonstrate high virulence and resistance factors. The correlation between these phylogroups, MDR, and ESBL production, along with the increasing infection rates associated with phylogroup A, suggests a potential for horizontal gene transfer. This underscores the urgent need for vigilant control measures.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"93-101"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emergence of the Delta and Omicron Variants of COVID-19 Clusters in a Long-term Care Hospital, Seoul, Korea: Focusing on Outbreak Epidemiology, Incidence, Fatality, and Vaccination. 韩国首尔一家长期护理医院出现 COVID-19 的 Delta 和 Omicron 变体群:重点关注疫情流行病学、发病率、死亡率和疫苗接种。
IF 2.8 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-01 DOI: 10.3947/ic.2024.0128
Geum-Hee Oh, Jeong Mi Park, Philip Kofie, Moo-Sik Lee

Background: Severe acute respiratory syndrome coronavirus 2, an RNA virus, exhibits variations in transmission power, severity rate, and vaccine effectiveness due to its mutable nature. We investigated the field epidemiological characteristics of the delta and omicron variants of coronavirus disease 2019 (COVID-19) clusters in a long-term care hospital.

Materials and methods: This study aimed to investigate the incidence, fatality, and vaccination effectiveness of confirmed COVID-19 cases caused by delta and omicron variants. The investigation focused on patients admitted to two long-term care hospitals in a Seoul autonomous district, comparing and analyzing relevant factors.

Results: Among the COVID-19 cases, 101 (34.3%) exhibited delta variants, while 193 (65.4%) showcased omicron variants. The incidence rate of omicron variants, compared to delta variants, was 2.24 times higher (95% confidence interval [CI], 1.68-3.00). This elevation was particularly notable in women across all age groups, patients, workers, and individuals with a history of three or more vaccinations. Deaths were reported in 13 cases (52.0%) with the delta variant and 12 cases (48.0%) with the omicron variant. The fatality rate of the omicron variant, in comparison to the delta variant, was 0.09 times (95% CI, 0.44-2.26), indicating no significant difference. No discernible variations in variables were observed.

Conclusion: The noteworthy surge in outbreaks among female patients, workers engaged in outdoor activities, and the apparent ineffectiveness of vaccination against omicron mutations underscore the need for careful consideration in formulating quarantine measures.

背景:严重急性呼吸综合征冠状病毒2是一种RNA病毒,由于其易变性,在传播能力、严重程度和疫苗有效性方面存在差异。目的调查某长期护理医院2019冠状病毒病(COVID-19)聚集型δ和组粒变异的现场流行病学特征。材料与方法:本研究旨在调查由delta和omicron变异引起的COVID-19确诊病例的发病率、病死率和疫苗接种效果。本次调查以首尔某自治地区的两家长期护理医院的住院患者为对象,对相关因素进行了比较和分析。结果:新冠肺炎病例中,δ型变异101例(34.3%),组粒型变异193例(65.4%)。组粒变异的发生率比δ变异高2.24倍(95%可信区间[CI], 1.68-3.00)。在所有年龄组的女性、患者、工人和有三次或更多疫苗接种史的个人中,这种升高尤为显著。δ型变异13例(52.0%)死亡,组粒型12例(48.0%)死亡。与δ变异相比,组粒变异的致死率为0.09倍(95% CI, 0.44-2.26),表明无显著差异。在变量中没有观察到明显的变化。结论:在女性患者、从事户外活动的工作人员中发生的疫情明显增加,以及针对组粒突变的疫苗接种效果明显不足,说明在制定隔离措施时需要慎重考虑。
{"title":"Emergence of the Delta and Omicron Variants of COVID-19 Clusters in a Long-term Care Hospital, Seoul, Korea: Focusing on Outbreak Epidemiology, Incidence, Fatality, and Vaccination.","authors":"Geum-Hee Oh, Jeong Mi Park, Philip Kofie, Moo-Sik Lee","doi":"10.3947/ic.2024.0128","DOIUrl":"10.3947/ic.2024.0128","url":null,"abstract":"<p><strong>Background: </strong>Severe acute respiratory syndrome coronavirus 2, an RNA virus, exhibits variations in transmission power, severity rate, and vaccine effectiveness due to its mutable nature. We investigated the field epidemiological characteristics of the delta and omicron variants of coronavirus disease 2019 (COVID-19) clusters in a long-term care hospital.</p><p><strong>Materials and methods: </strong>This study aimed to investigate the incidence, fatality, and vaccination effectiveness of confirmed COVID-19 cases caused by delta and omicron variants. The investigation focused on patients admitted to two long-term care hospitals in a Seoul autonomous district, comparing and analyzing relevant factors.</p><p><strong>Results: </strong>Among the COVID-19 cases, 101 (34.3%) exhibited delta variants, while 193 (65.4%) showcased omicron variants. The incidence rate of omicron variants, compared to delta variants, was 2.24 times higher (95% confidence interval [CI], 1.68-3.00). This elevation was particularly notable in women across all age groups, patients, workers, and individuals with a history of three or more vaccinations. Deaths were reported in 13 cases (52.0%) with the delta variant and 12 cases (48.0%) with the omicron variant. The fatality rate of the omicron variant, in comparison to the delta variant, was 0.09 times (95% CI, 0.44-2.26), indicating no significant difference. No discernible variations in variables were observed.</p><p><strong>Conclusion: </strong>The noteworthy surge in outbreaks among female patients, workers engaged in outdoor activities, and the apparent ineffectiveness of vaccination against omicron mutations underscore the need for careful consideration in formulating quarantine measures.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"148-160"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-Communicable Diseases in Patients with Human Immunodeficiency Virus and Their Risk Factors. 人类免疫缺陷病毒患者的非传染性疾病及其风险因素。
IF 2.8 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-01 DOI: 10.3947/ic.2024.0123
Dian Daniella, Anak Agung Ayu Yuli Gayatri, I Ketut Agus Somia

Background: The increasingly widespread use of antiretroviral drugs (ARV) to manage human immunodeficiency virus (HIV) infection has significantly reduced mortality. Accordingly, the number of patients with HIV with a life expectancy >50 years is increasing. With advanced age, the risk of non-communicable diseases (NCD) increases. According to a study in Uganda in 2017, the prevalence of at least one NCD in patients with HIV was 20.7%, with 11-30% of deaths due to NCDs, especially cardiovascular disease. This emphasizes that NCDs in patients with HIV are of clinical concern, as are the factors that increase the risk of these diseases. However, most studies on HIV and NCDs focus on African countries, while research in Asia is limited. Differences in genetics, lifestyle, and co-existing health burdens may influenced NCD prevalence and risk factors. This study aimed to determine the prevalence of and risk factors for NCDs in patients with HIV.

Materials and methods: This was an analytical cross-sectional study conducted at the outpatient clinic of the Ngoerah Hospital from June 8, 2023, to July 7, 2023. Descriptive and multivariate analyses were performed.

Results: In total, 1,644 patients with HIV were included in this study. The prevalence of NCDs was 1.9% for hypertension, 1.1% for diabetes mellitus, 0.7% for dyslipidemia, 1.0% for kidney disorders, 0.1% for stroke, 0.3% for cancer, 0.3% for cardiovascular disease, and 0.2% for autoimmune diseases. After conducting a multivariate test, we found that age >50 years increased the risk of comorbid NCDs by 7.886 times, while male sex increased the risk by 2.568 times, and an ARV regimen of two nucleoside reverse transcriptase inhibitors (NRTIs) + non-NRTI (NNRTI) decreased the risk by 2.625 times.

Conclusion: Hypertension was the most common NCD in patients with HIV, followed by diabetes mellitus. Male patients and those aged >50 years were at a greater risk of developing NCDs, whereas a history of using the two NRTIs + NNRTI regimen was associated with a lower risk of NCDs.

背景:越来越广泛地使用抗逆转录病毒药物(ARV)来治疗人类免疫缺陷病毒(HIV)感染,大大降低了死亡率。因此,预期寿命在50岁以下的艾滋病毒患者数量正在增加。随着年龄的增长,患非传染性疾病的风险也在增加。根据2017年乌干达的一项研究,艾滋病毒患者中至少有一种非传染性疾病的患病率为20.7%,其中11-30%的死亡是由非传染性疾病,特别是心血管疾病造成的。这强调艾滋病毒患者的非传染性疾病是临床关注的问题,增加这些疾病风险的因素也是临床关注的问题。然而,大多数关于艾滋病毒和非传染性疾病的研究集中在非洲国家,而在亚洲的研究有限。遗传、生活方式和共存的健康负担的差异可能影响非传染性疾病的流行和风险因素。本研究旨在确定艾滋病毒感染者中非传染性疾病的患病率和危险因素。材料和方法:这是一项分析性横断面研究,于2023年6月8日至2023年7月7日在Ngoerah医院门诊进行。进行了描述性和多变量分析。结果:本研究共纳入1644例HIV患者。非传染性疾病的患病率高血压为1.9%,糖尿病为1.1%,血脂异常为0.7%,肾病为1.0%,中风为0.1%,癌症为0.3%,心血管疾病为0.3%,自身免疫性疾病为0.2%。在进行多因素检验后,我们发现,年龄在50岁至50岁之间的人群共患病NCDs的风险增加了7.886倍,而男性增加了2.568倍,两种核苷类逆转录酶抑制剂(nrti) +非nrti (NNRTI)的ARV方案降低了2.625倍的风险。结论:HIV感染者中最常见的非传染性疾病是高血压,其次是糖尿病。男性患者和年龄在50岁至50岁之间的患者发生非传染性疾病的风险更高,而使用两种nrti + NNRTI方案的历史与较低的非传染性疾病风险相关。
{"title":"Non-Communicable Diseases in Patients with Human Immunodeficiency Virus and Their Risk Factors.","authors":"Dian Daniella, Anak Agung Ayu Yuli Gayatri, I Ketut Agus Somia","doi":"10.3947/ic.2024.0123","DOIUrl":"10.3947/ic.2024.0123","url":null,"abstract":"<p><strong>Background: </strong>The increasingly widespread use of antiretroviral drugs (ARV) to manage human immunodeficiency virus (HIV) infection has significantly reduced mortality. Accordingly, the number of patients with HIV with a life expectancy >50 years is increasing. With advanced age, the risk of non-communicable diseases (NCD) increases. According to a study in Uganda in 2017, the prevalence of at least one NCD in patients with HIV was 20.7%, with 11-30% of deaths due to NCDs, especially cardiovascular disease. This emphasizes that NCDs in patients with HIV are of clinical concern, as are the factors that increase the risk of these diseases. However, most studies on HIV and NCDs focus on African countries, while research in Asia is limited. Differences in genetics, lifestyle, and co-existing health burdens may influenced NCD prevalence and risk factors. This study aimed to determine the prevalence of and risk factors for NCDs in patients with HIV.</p><p><strong>Materials and methods: </strong>This was an analytical cross-sectional study conducted at the outpatient clinic of the Ngoerah Hospital from June 8, 2023, to July 7, 2023. Descriptive and multivariate analyses were performed.</p><p><strong>Results: </strong>In total, 1,644 patients with HIV were included in this study. The prevalence of NCDs was 1.9% for hypertension, 1.1% for diabetes mellitus, 0.7% for dyslipidemia, 1.0% for kidney disorders, 0.1% for stroke, 0.3% for cancer, 0.3% for cardiovascular disease, and 0.2% for autoimmune diseases. After conducting a multivariate test, we found that age >50 years increased the risk of comorbid NCDs by 7.886 times, while male sex increased the risk by 2.568 times, and an ARV regimen of two nucleoside reverse transcriptase inhibitors (NRTIs) + non-NRTI (NNRTI) decreased the risk by 2.625 times.</p><p><strong>Conclusion: </strong>Hypertension was the most common NCD in patients with HIV, followed by diabetes mellitus. Male patients and those aged >50 years were at a greater risk of developing NCDs, whereas a history of using the two NRTIs + NNRTI regimen was associated with a lower risk of NCDs.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"131-137"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RSV Prevention Strategies in Korean Children: A Review of Current Approaches and Emerging Options. 韩国儿童 RSV 预防策略:当前方法和新兴方案回顾。
IF 2.8 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-01 DOI: 10.3947/ic.2024.0122
Hyun Jung Kim, Sujin Choi, Young June Choe

Respiratory syncytial virus (RSV) poses a significant threat to infants and young children in Korea and globally. Current preventive measures, such as palivizumab, have limitations, necessitating the exploration of new strategies. Nirsevimab, a long-acting monoclonal antibody, has emerged as a promising option for protecting all infants from RSV. Clinical trials and real-world evidence support its effectiveness in reducing RSV-related hospitalizations. The economic burden of RSV infection in Korea underscores the need for cost-effective interventions. While several RSV vaccines are under development, none are currently available in Korea. Maternal immunization programs and vaccines for older infants offer potential avenues for expanding protection. This review highlights the evolving landscape of RSV prevention, with a shift towards nirsevimab and future vaccines. Further research is crucial to understand the long-term consequences of RSV infection and develop comprehensive prevention strategies tailored to the Korean population.

呼吸道合胞病毒(RSV)对韩国乃至全球的婴幼儿都构成了严重威胁。目前的预防措施(如帕利珠单抗)存在局限性,因此有必要探索新的策略。Nirsevimab 是一种长效单克隆抗体,已成为保护所有婴儿免受 RSV 感染的一种有前途的选择。临床试验和真实世界的证据都证明了它在减少 RSV 相关住院治疗方面的有效性。在韩国,RSV 感染造成的经济负担凸显了采取具有成本效益的干预措施的必要性。虽然有几种 RSV 疫苗正在研发中,但目前在韩国还没有上市。孕产妇免疫计划和大龄婴儿疫苗为扩大保护范围提供了潜在途径。本综述强调了 RSV 预防的演变趋势,即转向使用 nirsevimab 和未来的疫苗。进一步的研究对于了解 RSV 感染的长期后果和制定适合韩国人口的综合预防策略至关重要。
{"title":"RSV Prevention Strategies in Korean Children: A Review of Current Approaches and Emerging Options.","authors":"Hyun Jung Kim, Sujin Choi, Young June Choe","doi":"10.3947/ic.2024.0122","DOIUrl":"10.3947/ic.2024.0122","url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) poses a significant threat to infants and young children in Korea and globally. Current preventive measures, such as palivizumab, have limitations, necessitating the exploration of new strategies. Nirsevimab, a long-acting monoclonal antibody, has emerged as a promising option for protecting all infants from RSV. Clinical trials and real-world evidence support its effectiveness in reducing RSV-related hospitalizations. The economic burden of RSV infection in Korea underscores the need for cost-effective interventions. While several RSV vaccines are under development, none are currently available in Korea. Maternal immunization programs and vaccines for older infants offer potential avenues for expanding protection. This review highlights the evolving landscape of RSV prevention, with a shift towards nirsevimab and future vaccines. Further research is crucial to understand the long-term consequences of RSV infection and develop comprehensive prevention strategies tailored to the Korean population.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"31-37"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Mortality of Colistin Monotherapy vs. Colistin-Sulbactam for Carbapenem-Resistant Acinetobacter baumannii Pneumonia: A Propensity Score Analysis. 粘菌素单药治疗与粘菌素舒巴坦治疗耐碳青霉烯鲍曼不动杆菌肺炎的死亡率:倾向评分分析。
IF 2.8 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-01 DOI: 10.3947/ic.2024.0125
Nadia Cheh-Oh, Chutchawan Ungthammakhun, Dhitiwat Changpradub, Wichai Santimaleeworagun

Background: This study compared the mortality rates within 30 days of 2 different doses of sulbactam (6 g and 9-12 g daily) when used in colistin (COL)-based treatment regimens and COL monotherapy for carbapenem-resistant Acinetobacter baumannii (CRAB).

Materials and methods: This retrospective cohort study included 234 participants diagnosed with severe pneumonia due to CRAB infection at Phramongkutklao Hospital, Thailand, from July 1, 2011, to April 30, 2023. Participants were categorized into three groups: COL monotherapy, COL with 6 g of sulbactam daily (COL+S6g), and COL with 9-12 g of sulbactam daily (COL+SHD). Following the exclusion of patients with renal impairment (serum creatinine ≥1.5 mg/dl), a 1:2 propensity score (PS) matching was used to ensure comparable groups, with the COL group designated as the control. The matching variables included age, APACHE II scores, serum creatinine, intensive care units admission, and bacteremia. The number of participants in each group was as follows: 19 in COL, 32 in COL+S6g, and 38 in COL+SHD. The primary outcomes assessed were all-cause mortality rates at 7, 14, and 30 days. Kaplan-Meier survival curves and the Log-rank test were used to evaluate differences between groups, while multivariate Cox regression models were applied to determine the impact of treatment regimens.

Results: The unmatching PS analysis indicated that the COL+SHD regimen significantly reduces mortality compared to the COL regimen; hazard ratios (HR) were 0.18 (95% confidence interval [CI], 0.06-0.55) for 7-day mortality and 0.53 (95% CI,-0.29-0.97) for 30-day mortality. In addition, the COL+SHD regimen also lowered mortality more than the COL+S6g regimen within 7 days (HR, 0.29; 95% CI, 0.11-0.75). After PS matching, the COL+SHD regimen significantly reduced 7-day mortality compared to the COL regimen (adjusted HR, 0.24; 95% CI, -0.07-0.82). However, COL+S6g did not differ in mortality from either COL+SHD or COL for 7-day mortality. At 14 days and 30 days, there were no significant regimens to reduce mortality.

Conclusion: Combining COL+SHD effectively reduced death in 7 days from severe pneumonia in CRAB infection treatment.

背景:本研究比较了两种不同剂量舒巴坦(每天6克和9-12克)在以粘菌素(COL)为基础的治疗方案和COL单药治疗耐碳青霉烯鲍曼不动杆菌(CRAB)时30天内的死亡率。材料和方法:这项回顾性队列研究纳入了2011年7月1日至2023年4月30日期间在泰国Phramongkutklao医院诊断为因螃蟹感染而严重肺炎的234名参与者。参与者被分为三组:COL单药治疗,COL每日6克舒巴坦(COL+S6g), COL每日9-12克舒巴坦(COL+SHD)。排除肾功能损害患者(血清肌酐≥1.5 mg/dl)后,采用1:2倾向评分(PS)匹配来确保可比较组,以COL组为对照组。匹配变量包括年龄、APACHEⅱ评分、血清肌酐、重症监护病房入住情况和菌血症。各组受试者人数:COL组19人,COL+S6g组32人,COL+SHD组38人。评估的主要结局是7、14和30天的全因死亡率。Kaplan-Meier生存曲线和Log-rank检验用于评估组间差异,多变量Cox回归模型用于确定治疗方案的影响。结果:非匹配PS分析显示,与COL方案相比,COL+SHD方案显著降低死亡率;7天死亡率的风险比(HR)为0.18(95%可信区间[CI], 0.06-0.55), 30天死亡率的风险比为0.53 (95% CI,-0.29-0.97)。此外,COL+SHD方案在7天内的死亡率也比COL+S6g方案更低(HR, 0.29;95% ci, 0.11-0.75)。PS匹配后,与COL方案相比,COL+SHD方案显著降低了7天死亡率(调整HR, 0.24;95% ci, -0.07-0.82)。然而,COL+S6g的死亡率与COL+SHD或COL的7天死亡率没有差异。在第14天和第30天,没有显著降低死亡率的方案。结论:COL+SHD联合治疗可有效降低重症肺炎螃蟹感染患者7天死亡率。
{"title":"The Mortality of Colistin Monotherapy <i>vs.</i> Colistin-Sulbactam for Carbapenem-Resistant <i>Acinetobacter baumannii</i> Pneumonia: A Propensity Score Analysis.","authors":"Nadia Cheh-Oh, Chutchawan Ungthammakhun, Dhitiwat Changpradub, Wichai Santimaleeworagun","doi":"10.3947/ic.2024.0125","DOIUrl":"10.3947/ic.2024.0125","url":null,"abstract":"<p><strong>Background: </strong>This study compared the mortality rates within 30 days of 2 different doses of sulbactam (6 g and 9-12 g daily) when used in colistin (COL)-based treatment regimens and COL monotherapy for carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB).</p><p><strong>Materials and methods: </strong>This retrospective cohort study included 234 participants diagnosed with severe pneumonia due to CRAB infection at Phramongkutklao Hospital, Thailand, from July 1, 2011, to April 30, 2023. Participants were categorized into three groups: COL monotherapy, COL with 6 g of sulbactam daily (COL+S6g), and COL with 9-12 g of sulbactam daily (COL+SHD). Following the exclusion of patients with renal impairment (serum creatinine ≥1.5 mg/dl), a 1:2 propensity score (PS) matching was used to ensure comparable groups, with the COL group designated as the control. The matching variables included age, APACHE II scores, serum creatinine, intensive care units admission, and bacteremia. The number of participants in each group was as follows: 19 in COL, 32 in COL+S6g, and 38 in COL+SHD. The primary outcomes assessed were all-cause mortality rates at 7, 14, and 30 days. Kaplan-Meier survival curves and the Log-rank test were used to evaluate differences between groups, while multivariate Cox regression models were applied to determine the impact of treatment regimens.</p><p><strong>Results: </strong>The unmatching PS analysis indicated that the COL+SHD regimen significantly reduces mortality compared to the COL regimen; hazard ratios (HR) were 0.18 (95% confidence interval [CI], 0.06-0.55) for 7-day mortality and 0.53 (95% CI,-0.29-0.97) for 30-day mortality. In addition, the COL+SHD regimen also lowered mortality more than the COL+S6g regimen within 7 days (HR, 0.29; 95% CI, 0.11-0.75). After PS matching, the COL+SHD regimen significantly reduced 7-day mortality compared to the COL regimen (adjusted HR, 0.24; 95% CI, -0.07-0.82). However, COL+S6g did not differ in mortality from either COL+SHD or COL for 7-day mortality. At 14 days and 30 days, there were no significant regimens to reduce mortality.</p><p><strong>Conclusion: </strong>Combining COL+SHD effectively reduced death in 7 days from severe pneumonia in CRAB infection treatment.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"138-147"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply: Food, Water, Air, and Mind must Become Cleaner. 回复:食物、水、空气和思想必须变得更清洁。
IF 2.8 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-01 DOI: 10.3947/ic.2024.0149
Sheikh Mohd Saleem, Shah Sumaya Jan
{"title":"Reply: Food, Water, Air, and Mind must Become Cleaner.","authors":"Sheikh Mohd Saleem, Shah Sumaya Jan","doi":"10.3947/ic.2024.0149","DOIUrl":"10.3947/ic.2024.0149","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"183-184"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Poor Prognosis of Pneumococcal Co-Infection in Hospitalized Patients with COVID-19: A Propensity Score-Matched Analysis. COVID-19住院患者肺炎球菌合并感染的不良预后:倾向评分匹配分析
IF 2.8 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-01 DOI: 10.3947/ic.2024.0130
Soyoon Hwang, Eunkyung Nam, Shin-Woo Kim, Hyun-Ha Chang, Yoonjung Kim, Sohyun Bae, Nan Young Lee, Yu Kyung Kim, Ji Sun Kim, Han Wook Park, Joon Gyu Bae, Juhwan Jeong, Ki Tae Kwon

The impact of Streptococcus pneumoniae coinfection on coronavirus disease 2019 (COVID-19) prognosis remains uncertain. We conducted a retrospective analysis of patients hospitalized with COVID-19 who underwent a pneumococcal urinary antigen (PUA) test to assess its clinical utility. Results showed that PUA-positive patients required more oxygen support, high-flow nasal cannula, and dexamethasone compared to PUA-negative patients. Furthermore, the significantly higher incidence of a National Early Warning Score ≥5 in the PUA-positive group (P<0.001) suggests that a positive PUA test is associated with a severe disease course. However, no significant difference in mortality was observed between the two groups, and antibiotics were used in almost all patients (96.2%). While the PUA test may help guide antibiotic use in COVID-19 patients, its interpretation should be approached with caution.

肺炎链球菌合并感染对2019冠状病毒病(COVID-19)预后的影响尚不确定。我们对接受肺炎球菌尿抗原(PUA)检测的COVID-19住院患者进行了回顾性分析,以评估其临床效用。结果显示,与pua阴性患者相比,pua阳性患者需要更多的氧支持、高流量鼻插管和地塞米松。此外,pua阳性组国家预警评分≥5的发生率显著高于对照组(P
{"title":"Poor Prognosis of Pneumococcal Co-Infection in Hospitalized Patients with COVID-19: A Propensity Score-Matched Analysis.","authors":"Soyoon Hwang, Eunkyung Nam, Shin-Woo Kim, Hyun-Ha Chang, Yoonjung Kim, Sohyun Bae, Nan Young Lee, Yu Kyung Kim, Ji Sun Kim, Han Wook Park, Joon Gyu Bae, Juhwan Jeong, Ki Tae Kwon","doi":"10.3947/ic.2024.0130","DOIUrl":"10.3947/ic.2024.0130","url":null,"abstract":"<p><p>The impact of <i>Streptococcus pneumoniae</i> coinfection on coronavirus disease 2019 (COVID-19) prognosis remains uncertain. We conducted a retrospective analysis of patients hospitalized with COVID-19 who underwent a pneumococcal urinary antigen (PUA) test to assess its clinical utility. Results showed that PUA-positive patients required more oxygen support, high-flow nasal cannula, and dexamethasone compared to PUA-negative patients. Furthermore, the significantly higher incidence of a National Early Warning Score ≥5 in the PUA-positive group (<i>P</i><0.001) suggests that a positive PUA test is associated with a severe disease course. However, no significant difference in mortality was observed between the two groups, and antibiotics were used in almost all patients (96.2%). While the PUA test may help guide antibiotic use in COVID-19 patients, its interpretation should be approached with caution.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"172-178"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pertussis in the Post-COVID-19 Era: Resurgence, Diagnosis, and Management. 后covid -19时代的百日咳:死灰复燃、诊断和管理。
IF 2.8 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-01 DOI: 10.3947/ic.2024.0117
Hyun Mi Kang, Taek-Jin Lee, Su Eun Park, Soo-Han Choi

Pertussis is endemic worldwide, with epidemics occurring every 2 to 5 years despite a high vaccination coverage. After limited circulation during the coronavirus disease 2019 (COVID-19) pandemic, pertussis cases have increased rapidly worldwide since mid-late 2023, returning to pre-pandemic patterns. In Korea, 90 cases of pertussis were reported from April 2020 to May 2023, with elderly individuals aged ≥65 years accounting for 48.9%. Pertussis cases have increased sharply since June 2024, showing a nationwide epidemic, with a large increase among adolescents aged 13-15 years. As of August 2024, the national incidence rate of pertussis was estimated to be 37.75 per 100,000 population, with the highest incidence of 526.2 per 100,000 population in 13-year-olds. In Europe, during 2023-2024, an increase in pertussis incidence among infants was observed, along with large increases in 10-19-year-olds. In China, the number of reported cases of pertussis has increased rapidly since late 2023, with an age shift to older children, increase of vaccine escape, and a marked increase in the prevalence of macrolide-resistant Bordetella pertussis. The recent global resurgence of pertussis is due to decreased opportunities for boosting immunity by natural infection during the COVID-19 pandemic in combination with waning of immunity-induced pertussis vaccines.

百日咳在世界范围内流行,尽管疫苗接种率很高,但每2至5年发生一次流行病。经过2019冠状病毒病(COVID-19)大流行期间的有限传播,自2023年中后期以来,百日咳病例在全球范围内迅速增加,恢复到大流行前的模式。在韩国,2020年4月至2023年5月报告了90例百日咳,年龄≥65岁的老年人占48.9%。自2024年6月以来,百日咳病例急剧增加,在全国范围内流行,其中13-15岁的青少年人数大幅增加。截至2024年8月,全国百日咳发病率估计为每10万人37.75例,其中13岁儿童发病率最高,为每10万人526.2例。在欧洲,在2023-2024年期间,观察到婴儿百日咳发病率增加,同时10-19岁儿童百日咳发病率也大幅增加。在中国,自2023年底以来,报告的百日咳病例数迅速增加,年龄转移到较大的儿童,疫苗逃逸增加,以及耐大环内酯百日咳博德泰拉的患病率显着增加。最近全球百日咳死灰复燃是由于COVID-19大流行期间通过自然感染增强免疫力的机会减少,以及免疫诱导百日咳疫苗的减少。
{"title":"Pertussis in the Post-COVID-19 Era: Resurgence, Diagnosis, and Management.","authors":"Hyun Mi Kang, Taek-Jin Lee, Su Eun Park, Soo-Han Choi","doi":"10.3947/ic.2024.0117","DOIUrl":"10.3947/ic.2024.0117","url":null,"abstract":"<p><p>Pertussis is endemic worldwide, with epidemics occurring every 2 to 5 years despite a high vaccination coverage. After limited circulation during the coronavirus disease 2019 (COVID-19) pandemic, pertussis cases have increased rapidly worldwide since mid-late 2023, returning to pre-pandemic patterns. In Korea, 90 cases of pertussis were reported from April 2020 to May 2023, with elderly individuals aged ≥65 years accounting for 48.9%. Pertussis cases have increased sharply since June 2024, showing a nationwide epidemic, with a large increase among adolescents aged 13-15 years. As of August 2024, the national incidence rate of pertussis was estimated to be 37.75 per 100,000 population, with the highest incidence of 526.2 per 100,000 population in 13-year-olds. In Europe, during 2023-2024, an increase in pertussis incidence among infants was observed, along with large increases in 10-19-year-olds. In China, the number of reported cases of pertussis has increased rapidly since late 2023, with an age shift to older children, increase of vaccine escape, and a marked increase in the prevalence of macrolide-resistant <i>Bordetella pertussis</i>. The recent global resurgence of pertussis is due to decreased opportunities for boosting immunity by natural infection during the COVID-19 pandemic in combination with waning of immunity-induced pertussis vaccines.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"13-30"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis of Pneumocystis jirovecii Pneumonia in Non-HIV Immunocompromised Patient in Korea: A Review and Algorithm Proposed by Expert Consensus Group.
IF 2.8 Q2 INFECTIOUS DISEASES Pub Date : 2025-03-01 Epub Date: 2025-01-20 DOI: 10.3947/ic.2024.0148
Raeseok Lee, Kyungmin Huh, Chang Kyung Kang, Yong Chan Kim, Jung Ho Kim, Hyungjin Kim, Jeong Su Park, Ji Young Park, Heungsup Sung, Jongtak Jung, Chung-Jong Kim, Kyoung-Ho Song

Pneumocystis jirovecii pneumonia (PJP) is a life-threatening infection commonly observed in immunocompromised patients, necessitating prompt diagnosis and treatment. This review evaluates the diagnostic performance of various tests used for PJP diagnosis through a comprehensive literature review. Additionally, we propose a diagnostic algorithm tailored to non-human immunodeficiency virus immunocompromised patients, considering the specific characteristics of current medical resources in Korea.

{"title":"Diagnosis of <i>Pneumocystis jirovecii</i> Pneumonia in Non-HIV Immunocompromised Patient in Korea: A Review and Algorithm Proposed by Expert Consensus Group.","authors":"Raeseok Lee, Kyungmin Huh, Chang Kyung Kang, Yong Chan Kim, Jung Ho Kim, Hyungjin Kim, Jeong Su Park, Ji Young Park, Heungsup Sung, Jongtak Jung, Chung-Jong Kim, Kyoung-Ho Song","doi":"10.3947/ic.2024.0148","DOIUrl":"10.3947/ic.2024.0148","url":null,"abstract":"<p><p><i>Pneumocystis jirovecii</i> pneumonia (PJP) is a life-threatening infection commonly observed in immunocompromised patients, necessitating prompt diagnosis and treatment. This review evaluates the diagnostic performance of various tests used for PJP diagnosis through a comprehensive literature review. Additionally, we propose a diagnostic algorithm tailored to non-human immunodeficiency virus immunocompromised patients, considering the specific characteristics of current medical resources in Korea.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"45-62"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Infection and Chemotherapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1